Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Discontinued
Reference number: GID-TA10897
Following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available in due course.